CD274 and craniopharyngioma: The utility of a given biomarker such as TMB, MSI, or PD-L1 to correlate with therapeutic response to immune checkpoint inhibitors is lineage dependent and it is unknown if these types of agents would be efficacious for craniopharyngiomas.